2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 945

Pain, Functional Limitations and Physical Activity Participation Trajectories in Patients with Symptomatic Knee and Hip Osteoarthritis: A Multi-Trajectory Analysis
Abstract Number: 946

Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells
Abstract Number: 947

Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis
Abstract Number: 948

Effects of Antiretroviral Therapy with Tenofovir and Other Antiretroviral Drugs on the Inflammatory State and Bone Remodeling on Newly Diagnosed HIV-Patients at Basal and 3 Months after Starting Treatment
Abstract Number: 949

Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection
Abstract Number: 950

Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients
Abstract Number: 951

IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells
Abstract Number: 952

Effusion-Synovitis and Infrapatellar Fat Pad Edema Differentiate Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 953

Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later
Abstract Number: 954

A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
Abstract Number: 955

Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis
Abstract Number: 956

Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
Abstract Number: 957

Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
Abstract Number: 958

Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Abstract Number: 959

The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].